01—Abstract
Summary
Summary of the 10-Q filed July 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories reported increased net sales for the second quarter and first six months of 2024, driven primarily by growth in its Medical Devices, Nutritional Products, and Established Pharmaceutical Products segments.
This growth was achieved despite a significant decline in COVID-19 testing sales and unfavorable foreign exchange impacts due to a stronger U.S. dollar. Despite revenue growth, net earnings decreased year-over-year for both the quarter and the first six months, impacted by higher operating costs and expenses, including a loss on the sale of a non-core business and increased selling, general, and administrative expenses.
However, operational cash flow remained strong, indicating continued business health. Investors should monitor the ongoing legal proceedings related to infant formula and the company's significant tax exposure with the IRS, which could materially impact future results.
02—Key points
Key Highlights
- Total net sales increased by 4.0% (7.5% excluding foreign exchange) in Q2 2024 and 3.1% (6.3% excluding foreign exchange) for the first six months of 2024, demonstrating underlying business growth.
- Medical Devices segment continues to be a strong performer, with a 10.2% (12.4% excluding foreign exchange) increase in Q2 2024 sales, driven by double-digit growth in Diabetes Care, Electrophysiology, and Structural Heart.
- COVID-19 testing-related sales significantly declined, contributing to a 5.3% decrease in the Diagnostics segment sales in Q2 2024, a trend that is expected to continue.
- Net earnings for Q2 2024 decreased to $1.302 billion from $1.375 billion in Q2 2023, and for the first six months decreased to $2.527 billion from $2.693 billion, impacted by increased operating costs and a loss on the sale of a non-core business.
- The company is facing significant tax disputes with the IRS, with potential liabilities for 2017-2020 tax years amounting to over $1 billion.
- A jury awarded $495 million in a lawsuit alleging Abbott's infant formula products caused necrotizing enterocolitis (NEC); Abbott plans to appeal this verdict.
- Gross profit margin improved to 51.1% in Q2 2024 from 50.1% in Q2 2023, indicating effective cost management and pricing strategies.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2024, Abbott Laboratories kept $0.13.
- Revenue$10.38B100.0%
- Cost of revenue−$4.60B44.4%
- Gross profit$5.77B55.6%
- Operating costs−$4.11B39.6%
- Operating income$1.67B16.1%
- Interest, other & tax−$367.0M3.5%
- Net income$1.30B12.5%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed July 31, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $10.38B$9.98B | +4.0% |
| Cost of Revenue | $4.60B$4.48B | +2.7% |
| Gross Profit | $5.77B$5.50B | +5.1% |
| R&D Expenses | $698.00M$715.00M | −2.4% |
| SG&A Expenses | $2.94B$2.74B | +7.2% |
| Operating Expenses | $8.71B$8.44B | +3.2% |
| Operating Income | $1.67B$1.54B | +8.2% |
| Net Income | $1.30B$1.38B | −5.3% |
| EPS (Basic) | $0.74$0.79 | −6.3% |
| EPS (Diluted) | $0.74$0.78 | −5.1% |
| Shares Outstanding (Basic) | 1.74B1.74B | +0.2% |
| Shares Outstanding (Diluted) | 1.75B1.75B | +0.1% |
05—Questions
Frequently Asked Questions
What is the overall financial performance of Abbott Laboratories for the reported period?
Abbott Laboratories reported increased net sales for both the second quarter and the first six months of 2024, driven by strong performance in its Medical Devices, Nutritional Products, and Established Pharmaceutical Products segments. However, net earnings declined year-over-year for both periods due to increased operating costs, a loss on the sale of a non-core business, and higher selling, general, and administrative expenses. Despite the earnings dip, operational cash flow remained robust.
What are the key drivers of revenue growth and decline?
Revenue growth was primarily fueled by the Medical Devices segment, particularly in areas like Diabetes Care (FreeStyle Libre), Electrophysiology, and Structural Heart. Nutritional Products and Established Pharmaceutical Products also contributed positively. The main driver of revenue decline was the significant drop in COVID-19 testing-related sales, which impacted the Diagnostics segment, especially Rapid Diagnostics.
What are the significant risks or potential headwinds identified in the filing?
Two major risks are highlighted: first, ongoing legal proceedings, including a recent $495 million jury award related to infant formula and NEC claims (which Abbott intends to appeal), and second, significant tax disputes with the IRS for the 2017-2020 tax years, potentially involving over $1 billion in additional taxes. Additionally, foreign exchange rate fluctuations, particularly a stronger U.S. dollar, negatively impacted international sales.
How is the company managing its cost structure and profitability?
Abbott demonstrated an improvement in its gross profit margin, increasing to 51.1% in Q2 2024 from 50.1% in Q2 2023. This improvement was attributed to higher pricing, gross margin improvement initiatives, and partially offset by unfavorable foreign exchange. Research and development expenses decreased slightly in Q2 due to lower impairment charges, while Selling, General, and Administrative expenses increased, reflecting higher selling and marketing investments.
06—Continue